Myriad Genetics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Myriad Genetics han disminuido a una tasa media anual de -28.8%, mientras que en la industria Biotechs los beneficios crecieron en un 15.5% anualmente. Los ingresos han ido disminuyendo a una tasa media de 1.8% al año.

Información clave

-28.8%

Tasa de crecimiento de los beneficios

-25.9%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	-1.8%
Rentabilidad financiera	-30.9%
Margen neto	-30.3%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

Jun 05

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 11

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

May 09

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Mar 28

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02

Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system

Aug 25

Are Investors Undervaluing Myriad Genetics, Inc. (NASDAQ:MYGN) By 50%?

Aug 05

Myriad Genetics Q2 2022 Earnings Preview

Aug 03

Myriad Genetics touts study results of GeneSight test on depression remission rates

Jul 12

Desglose de ingresos y gastos

Cómo gana y gasta dinero Myriad Genetics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:MYGN Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	774	-235	562	91
31 Dec 23	753	-263	567	89
30 Sep 23	734	-274	575	91
30 Jun 23	699	-248	569	88
31 Mar 23	695	-146	551	87
31 Dec 22	678	-112	527	85
30 Sep 22	661	-77	444	83
30 Jun 22	672	-18	494	81
31 Mar 22	682	-8	513	80
31 Dec 21	691	-27	538	82
30 Sep 21	684	-57	599	80
30 Jun 21	662	-97	542	78
31 Mar 21	566	-148	514	76
31 Dec 20	557	-224	501	73
30 Sep 20	598	-194	499	74
30 Jun 20	639	-199	507	77
31 Mar 20	761	-148	539	81
31 Dec 19	813	-26	546	83
30 Sep 19	835	-15	547	86
30 Jun 19	851	5	557	86
31 Mar 19	830	23	512	83
31 Dec 18	796	26	479	80
30 Sep 18	767	54	451	74
30 Jun 18	744	133	435	71
31 Mar 18	749	130	444	72
31 Dec 17	763	126	459	71
30 Sep 17	771	101	472	73
30 Jun 17	729	17	440	74
31 Mar 17	757	32	446	75
31 Dec 16	751	63	414	75
30 Sep 16	748	94	385	73
30 Jun 16	741	117	359	71
31 Mar 16	757	121	349	70
31 Dec 15	747	108	349	69
30 Sep 15	738	95	351	70
30 Jun 15	723	80	366	76
31 Mar 15	722	95	354	77
31 Dec 14	725	110	350	74
30 Sep 14	745	137	335	73
30 Jun 14	778	176	327	68
31 Mar 14	764	187	314	60
31 Dec 13	737	188	291	61
30 Sep 13	682	172	273	58
30 Jun 13	613	147	252	54

Ingresos de calidad: MYGN actualmente no es rentable.

Margen de beneficios creciente: MYGN actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: MYGN no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 32.2% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de MYGN en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: MYGN no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-14.4%).

Rentabilidad financiera

Alta ROE: MYGN tiene una rentabilidad financiera negativa (-30.87%), ya que actualmente no es rentable.

Myriad Genetics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS misses analyst expectations

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Recent updates

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

CEO, President & Director recently sold US$5.7m worth of stock

CEO, President & Director notifies of intention to sell stock

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$0.93 loss

Price target increased by 8.9% to US$24.50

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings: EPS misses analyst expectations

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Consensus EPS estimates fall by 21%, revenue upgraded

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Shareholder dilution

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023

Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 8.2% to US$21.67

Bernstein Litowitz Berger & Grossmann LLP Proposes Settlement of Class Action Involving Persons Who Purchased or Acquired Myriad Genetics, Inc. Common Stock

Insufficient new directors

Consensus EPS estimates fall by 52%

Myriad Genetics Announces Enhancements to the Genesight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023

Myriad Genetics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Myriad Genetics, Inc. Announces Inclusion of Breast Density to Myrisk(R) with Riskscore(R) Breast Cancer Risk Assessment

Independent Director notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Adam Brufsky as Scientific Advisor

Consensus EPS estimates fall by 27%, revenue upgraded

Myriad Genetics, Inc. Revises Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.7% to US$21.72

Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 24%

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Hires Senior Leaders to Advance Commercial Growth Plans

Myriad Genetics, Inc. announces Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

High number of new directors

Price target decreased to US$20.44

Myriad Genetics Announces Urosuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-Driven Medical Information

Consensus EPS estimates fall by 103%

Price target decreased to US$22.19

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Myriad Genetics, Inc. (NasdaqGS:MYGN) acquired Gateway Genomics, LLC for approximately $110 million.

Myriad Genetics, Inc. Elects Paul M. Bisaro as New Board Member

High number of new directors

Myriad Genetics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Myriad: Trying To Find Its Footing In An Evolving Industry

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system

Price target increased to US$24.36

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind